Who is sponsoring NCT04237493?

NCT04237493 is sponsored by University of Jordan.

What drugs are being tested in NCT04237493?

Interventions in NCT04237493: Metformin and Glimepiride (Low Dosage), Metformin and Vildagliptin (Low Dosage), Metformin and Insulin Glargine U100 (Low Dosage), Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage), Metformin and Glimepiride (Regular Dosage), Metformin and Vildagliptin (Regular Dosage), Metformin and Insulin Glargine U100 (Regular Dosage), Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage).

What condition does NCT04237493 study?

NCT04237493 studies Diabetes Mellitus, Type 2.

Is NCT04237493 still recruiting?

NCT04237493 is currently completed. Last updated 11 February 2020.

Last reviewed 2020-02-11 · How we verify

NCT04237493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Completed Phase 4 Last updated 11 February 2020

What this trial tests

Phase 4 trial testing Metformin and Glimepiride (Low Dosage) in Diabetes Mellitus, Type 2 in 687 participants. Completed in 24 July 2017.

Timeline

14 February 2017

Primary endpoint
24 July 2017

24 July 2017

Quick facts

Lead sponsor	University of Jordan
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	687
Start date	14 February 2017
Primary completion	24 July 2017
Estimated completion	24 July 2017
Sites	1 location across Jordan

Drugs / interventions tested

Metformin and Glimepiride (Low Dosage) — full drug profile →
Metformin and Vildagliptin (Low Dosage) — full drug profile →
Metformin and Insulin Glargine U100 (Low Dosage) — full drug profile →
Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)
Metformin and Glimepiride (Regular Dosage) — full drug profile →
Metformin and Vildagliptin (Regular Dosage) — full drug profile →
Metformin and Insulin Glargine U100 (Regular Dosage)
Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

University of Jordan

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Every lunar year, during the month of Ramadan, Muslims abstain from food and drink between dawn and nightfall. People with type 2 diabetes who fast during Ramadan are at an increased risk of acute glycemic complications. Our aim is to investigate the effect of dosage reduction of four glucose-lowering multidrug regimens on the incidence of acute glycemic complications in people with type 2 diabetes who fast during Ramadan.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.
Zaghlol LY, Beirat AF, Amarin JZ, Hassoun Al Najar AM, et al · · 2021 · cited 5× · PMID 34305809 · DOI 10.3389/fendo.2021.613826
Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
Lee SWH, Chen WS, Sellappans R, Md Sharif SB, et al · · 2023 · cited 1× · PMID 37435938 · DOI 10.1002/14651858.cd013178.pub2

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other University of Jordan trials

Trials by the same sponsor.

NCT07370545 — Impact of Presentation Sequence on Patient Tooth Shade Selection · NA · completed
NCT07279285 — Sweet-Tasting Solution Versus Placebo to Reduce Pain During Local Anesthetic Injection in Children · NA · not yet recruiting
NCT07310485 — Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausa · NA · enrolling by invitation
NCT06977009 — Influence of Occlusal Reduction on Endodontic Postoperative Pain · NA · recruiting
NCT07212413 — Effect of Snow-plow Technique on the Postoperative Pain Following Direct Composite Restoration · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04237493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Jordan
Last refreshed: 11 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04237493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing